Open-Label, Two-Period Phase 1 Study in Healthy Subjects to Evaluate the Potential Effect of Multiple Doses of Paroxetine on the Pharmacokinetics and Safety of HBI-3000
Latest Information Update: 18 Jul 2022
At a glance
- Drugs Sulcardine (Primary) ; Paroxetine
- Indications Atrial fibrillation
- Focus Pharmacokinetics
- Sponsors HUYA Bioscience International
- 17 May 2022 Status changed from recruiting to completed according to a HUYABIO International media release.
- 14 Jun 2021 Planned End Date changed from 1 Jun 2021 to 1 Aug 2021.
- 14 Jun 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Aug 2021.